BEARINGPOINT
22.4.2021 09:57:05 CEST | Business Wire | Press release
Climate change is increasing pressure on companies to take immediate actions to measure, manage, and report greenhouse gas emissions from their operations and value chains. In its recent client story, management and technology consultancy BearingPoint shows how it supported Wipak, a global supplier of packaging solutions and services, in taking a significant step on its journey to reducing its carbon footprint to zero by 2025 by accurately calculating its carbon emissions and gaining transparency across the entire product life-cycle process.
BearingPoint leveraged its Emissions Calculator solution and used a cradle-to-gate approach during a series of workshops to identify Wipak’s key impact areas and aligned them with data requirements. The team then analyzed the processes and data availability for material acquisition, freight transportation, manufacturing sites, warehouses, and support processes related to sales offices and business travel. All data was centralized in a collection plan to feed BearingPoint’s standard data templates, followed by integrating it into the software solution. This resulted in a corporate carbon footprint (CCF), including scopes 1, 2, and 3 according to the Greenhouse Gas Protocol (GHG). Wipak also added the product carbon footprint (PCF) module to support sharing carbon data with clients down to the product level. BearingPoint supported the client to select the allocation methods and relevant secondary data sources, determining every product’s climate impact, from raw material sourcing to their recycling or disposal.
Mika Niemelä, Partner at BearingPoint: “Consumer perception and corporate customers’ demands regarding sustainable packaging are driving Wipak to seek flexible and resource-efficient solutions. At the same time, Wipak needed to ensure accurate carbon footprint calculations to comply with future sustainability regulations and laws, and it now can with our Emission Calculator solution. Today, with our solution, the company is well on its way to achieving a zero-carbon footprint by 2025.”
Wipak can now accurately calculate its carbon emissions that allow for tracking its achievements toward decarbonization on a daily level. Already from the validation phase, the application assesses and summarizes more than 1,400 purchased goods, 3,500 semi-finished products, and 4,700 finished products daily, based on a big data approach.
BearingPoint’s Emissions Calculator also enables the company to make data-driven business decisions toward reducing its carbon footprint to zero by 2025, based on all information centralized in one place and analytic tool-derived insights. The solution offers a comprehensive picture of which region, business line, or product is causing the highest emissions. Wipak also benefits from continuous updates from leading standards such as GHG protocol, ISO 14064, ISO 14067, or GLEC. This ensures that the company is better prepared to meet internal audit requirements, as well as to comply with future sustainability regulations and laws.
Dorit Nelke-Bruhn, Manager Sustainability Processes and Patents, Wipak Group: “To support us on our journey to become the most sustainable flexible packaging company, we were searching for a professional and trusted carbon accounting software to calculate corporate and product carbon footprints. BearingPoint’s Emissions Calculator fulfills our needs. It supports us to assess GHG emissions of raw materials, our production facilities, freight transportation, and support processes such as business travel and sales offices and to identify emission reduction potentials.”
About Wipak Group
Wipak is part of the family owned Wihuri Group, a diverse Finnish conglomerate that can trace its origins back over 100 years. Today the Wihuri group employs 5,000 people with operations in 30 countries.
Wihuri´s Packaging business is one of the world's leading producers of packaging materials and solutions for the Food and Medical supply industries in Europe and North America. Wihuri’s Packaging Division consists of two international brands: WIPAK in Europe and Asia and WINPAK in North America. More information about Winpak can be found below.
Wipak develops and manufactures highly innovative premium-quality flexible packaging solutions for Food products and Medical Instruments and Devices.
www.wipak.com
https://www.linkedin.com/company/wipak/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units. The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business-critical services to its clients, supporting their business success. The third unit provides the software for successful digital transformation. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom